Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVTX 006

Drug Profile

AVTX 006

Alternative Names: AEVI-006; ASP 7486; AVTX-006; CERC-006; OSI-027

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Aevi Genomic Medicine; OSI Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Imidazoles; Indoles; Pyrazines; Small molecules; Triazines
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphangioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphangioma; Lymphoma; Renal cancer; Solid tumours

Most Recent Events

  • 07 Mar 2022 Avelo Therapeutics withdraws a phase I trial prior enrolment for Lymphangioma in USA as Avelo Therapeutics decided to pursue strategic alternatives for the programme due to early positive results (PO) (NCT04994002)
  • 02 Mar 2022 Discontinued - Preclinical for Lymphangioma in USA (PO)
  • 26 Aug 2021 Cerecor is now called Avalo Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top